Crossmark

Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1

Crossref DOI link: https://doi.org/10.1186/s12885-018-4946-9

Published Online: 2018-10-26

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiao, Yang

Watts, Tanya

Xue, Jing

Hannafon, Bethany

Ding, Wei-Qun https://orcid.org/0000-0001-7358-3700
Funding

Funding for this research was provided by:

National Institute of General Medical Sciences of the National Institutes of Health (U54GM104938)

Oklahoma Center for the Advancement of Science and Technology (HR14-147)

American Cancer Society (CNE-117557)
License Information

Text and Data Mining valid from 2018-10-26
More Information

Article History

Received: 12 April 2018

Accepted: 12 October 2018

First Online: 26 October 2018

Ethics approval and consent to participate

: Athymic nude mice (Foxn1nu) were purchased from Envigo (United Kingdom) and were used for in vivo evaluation of Sorafenib and DHA in accordance with the Institute Animal Care and Use Committee procedures and guidelines (Institute IACUC Protocol 100,861–14-025-SSH). All human cell lines were approved for use in this study by the Institutional Review Board (IRB protocol 4381).

: Not applicable.

: The authors have no competing interest to disclose.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.